舍吲哚结构式
|
常用名 | 舍吲哚 | 英文名 | SERTINDOLE |
---|---|---|---|---|
CAS号 | 106516-24-9 | 分子量 | 440.941 | |
密度 | 1.4±0.1 g/cm3 | 沸点 | 592.1±50.0 °C at 760 mmHg | |
分子式 | C24H26ClFN4O | 熔点 | 95-100ºC | |
MSDS | 中文版 美版 | 闪点 | 311.9±30.1 °C | |
符号 |
GHS07 |
信号词 | Warning |
舍吲哚用途Sertindole是5-HT2A,5-HT2C,D2和αl受体拮抗剂。 |
中文名 | 舍吲哚 |
---|---|
英文名 | sertindole |
中文别名 | 1-[2-[4-[5-氯-1-(4-氟苯基)-1H-吲哚-3-基]-1-哌啶基]乙基]-2-咪唑啉酮 |
英文别名 | 更多 |
描述 | Sertindole是5-HT2A,5-HT2C,D2和αl受体拮抗剂。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.4±0.1 g/cm3 |
---|---|
沸点 | 592.1±50.0 °C at 760 mmHg |
熔点 | 95-100ºC |
分子式 | C24H26ClFN4O |
分子量 | 440.941 |
闪点 | 311.9±30.1 °C |
精确质量 | 440.177917 |
PSA | 40.51000 |
LogP | 5.26 |
外观性状 | off-white |
蒸汽压 | 0.0±1.7 mmHg at 25°C |
折射率 | 1.671 |
储存条件 | 2-8°C |
稳定性 | 从丙酮结晶,熔点154~155℃;或从异丙醇-乙酸乙酯中结晶,熔点166℃。 |
水溶解性 | DMSO: >10mg/mL |
分子结构 | 1、 摩尔折射率:120.24 2、 摩尔体积(cm3/mol):347.2 3、 等张比容(90.2K):918.4 4、 表面张力(dyne/cm):48.9 5、 极化率(10-24cm3):47.66 |
计算化学 | 1.疏水参数计算参考值(XlogP):4.1 2.氢键供体数量:1 3.氢键受体数量:3 4.可旋转化学键数量:5 5.互变异构体数量:2 6.拓扑分子极性表面积40.5 7.重原子数量:31 8.表面电荷:0 9.复杂度:623 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H315-H319-H335-H413 |
警示性声明 | P261-P305 + P351 + P338 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
危害码 (欧洲) | Xi: Irritant; |
风险声明 (欧洲) | 36/37/38 |
安全声明 (欧洲) | 26 |
危险品运输编码 | NONH for all modes of transport |
RTECS号 | NJ0621100 |
~87% 舍吲哚 106516-24-9 |
文献:Perregaard; Arnt; Bogeso; Hyttel; Sanchez Journal of Medicinal Chemistry, 1992 , vol. 35, # 6 p. 1092 - 1101 |
~% 舍吲哚 106516-24-9 |
文献:Journal of Medicinal Chemistry, , vol. 35, # 6 p. 1092 - 1101 |
~% 舍吲哚 106516-24-9 |
文献:Journal of Medicinal Chemistry, , vol. 35, # 6 p. 1092 - 1101 |
~% 舍吲哚 106516-24-9 |
文献:Journal of Medicinal Chemistry, , vol. 35, # 6 p. 1092 - 1101 |
~% 舍吲哚 106516-24-9 |
文献:Journal of Medicinal Chemistry, , vol. 35, # 6 p. 1092 - 1101 |
~% 舍吲哚 106516-24-9 |
文献:Journal of Medicinal Chemistry, , vol. 35, # 6 p. 1092 - 1101 |
~% 舍吲哚 106516-24-9 |
文献:Journal of Medicinal Chemistry, , vol. 35, # 6 p. 1092 - 1101 |
化合物(I)和化合物(Ⅱ)进行格氏反应后,生成物(Ⅲ)水解,即得产物。
An investigation of the stability of emerging new psychoactive substances.
Drug Test. Anal. 6(7-8) , 696-704, (2014) The evolving nature of new psychoactive substances (NPS) - often referred to as 'legal highs', 'designer drugs' or 'bath salts' - presents an evolving challenge for toxicologists. Apart from the detec... |
|
Differential effects of blockade of ERG channels on gamma oscillations and excitability in rat hippocampal slices.
Eur. J. Neurosci. 36(12) , 3628-35, (2012) Agents such as sertindole and astemizole affect heart action by inducing long-QT syndrome, suggesting that apart from their neuronal actions through histamine receptors, 5-HT2 serotonin receptors and ... |
|
Risperidone versus other atypical antipsychotics for schizophrenia.
Cochrane Database Syst. Rev. (1) , CD006626, (2011) In many countries of the industrialised world second-generation ("atypical") antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether a... |
1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one |
1-(2-{4-[5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl}ethyl)-2-imidazolidinone |
1-[2-[4-[5-chloro-1-(p-fluorophenyl)indol-3-yl]piperidino]ethyl]-2-imidazolidinone |
1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1h-indol-3-yl]-1-piperidinyl]ethyl]-2-imidazolidinone |
2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- |
2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl] |
1-(2-{4-[5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one |
MFCD00867749 |
Sertindole |